- Home
- MAX vs TRVI Comparison
MAX vs TRVI Comparison
Compare MAX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- TRVI
- Stock Information
- Founded
- MAX 2014
- TRVI 2011
- Country
- MAX United States
- TRVI United States
- Employees
- MAX N/A
- TRVI N/A
- Industry
- MAX Industrial Machinery/Components
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- TRVI Health Care
- Exchange
- MAX Nasdaq
- TRVI Nasdaq
- Market Cap
- MAX 582.4M
- TRVI 629.8M
- IPO Year
- MAX 2020
- TRVI 2019
- Fundamental
- Price
- MAX $10.66
- TRVI $5.96
- Analyst Decision
- MAX Buy
- TRVI Strong Buy
- Analyst Count
- MAX 7
- TRVI 8
- Target Price
- MAX $17.21
- TRVI $19.31
- AVG Volume (30 Days)
- MAX 382.8K
- TRVI 2.6M
- Earning Date
- MAX 07-30-2025
- TRVI 08-07-2025
- Dividend Yield
- MAX N/A
- TRVI N/A
- EPS Growth
- MAX N/A
- TRVI N/A
- EPS
- MAX 0.28
- TRVI N/A
- Revenue
- MAX $1,002,364,000.00
- TRVI N/A
- Revenue This Year
- MAX $24.09
- TRVI N/A
- Revenue Next Year
- MAX $11.18
- TRVI N/A
- P/E Ratio
- MAX $38.36
- TRVI N/A
- Revenue Growth
- MAX 148.62
- TRVI N/A
- 52 Week Low
- MAX $7.33
- TRVI $2.36
- 52 Week High
- MAX $20.91
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- MAX 55.12
- TRVI 43.31
- Support Level
- MAX $10.70
- TRVI $6.05
- Resistance Level
- MAX $11.13
- TRVI $6.49
- Average True Range (ATR)
- MAX 0.33
- TRVI 0.53
- MACD
- MAX -0.06
- TRVI -0.05
- Stochastic Oscillator
- MAX 41.42
- TRVI 27.62
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.